News & Events

Northern New England Clinical & Translational Research (NNE-CTR) successes, events and news.


Archived Program Recordings

March 3, 2020 by User Not Found

Find a comprehensive archive of the NNE-CTR & UVMCC Seminar Series, plus links to recorded programs of interest to the IDeA community.

The Role of Tumor-associated Mesenchymal Cells in Breast Cancer Progression and Intervention by Jonathan Gordon, PhD, Assistant Professor, Department of Biochemistry, UVM (recorded November 8, 2019)
Many tumors are associated with a surrounding cell layer that while not cancerous, can contribute to progression of cancer to a metastatic state.  Using a multipronged RNAseq-based strategy, a distinct population of mesenchymal stromal cells were identified in patients with invasive breast cancer.  The identified tumor-associated mesenchymal stromal cells may provide a therapeutic strategy to prevent metastatic bone disease and identify indicators of progression in primary tumors.


QIAGEN Digital Insights by Dr. Eric Seiser, Senior Field Application Specialist (recorded January 10, 2020)
Our CLC bio, Ingenuity, Omicsoft and BIOBASE product lines combine powerful analytics and visualizations with the largest curated repository of biological and clinical findings.


Simultaneous Proteomics and Transcriptomics: TotalSeq and the Future of Single Cell Analysis by Christopher Gould, PhD, Technical Applications Scientist II, BioLegend (recorded November 1, 2019)
Welcome to the new era of single cell analysis.  New advances in single cell RNA-seq are expanding the ability for researchers to analyze surface immunophenotype and transcriptome at immense depth.  As such, BioLegend now offers TotalSeq antibodies.  These antibody-oligonucleotide conjugates seamlessly integrate with existing single cell RNA-seq protocols (eg CITE-seq) aimed at simultaneous protein and RNA measurement from single cells.  The oligos provide a permanent antibody tag using a barcode embedded in their sequence.  This allows for not only highly multiplexed measurement of dozens of cell surface molecules (220+), but, also the ability to combine multiple samples into one run using cell hashing.  We discuss the basic principles of CITE-seq and some practical considerations when looking to incorporate these new methodologies into your current workflows.  Data generated both at BioLegend and with collaborators at the New York Genome Center are reviewed.


RNAscope Technology by the Microscopy Imaging Center (recorded November 30, 2018)
RNAscope is an RNA in situ detection platform.  The RNAscope® Assays are based on the proprietary RNAscope® Technology, enabling RNA target expression analysis within intact cells and tissues with high sensitivity and specificity.  The innovative RNAscope® Assay, with in situ hybridization technology to detect mRNA and ncRNA targets of >300bp, was launched in 2011 and marks the foundation of our product portfolio.  The proprietary probe design requires an average of 20 Z pairs per target, however a minimum hybridization of 6 Z pairs can be used to obtain a signal. With over 1,400 publications in peer-reviewed journals, across multiple disciplines, the RNAscope® Assay represents a revolutionary advance in in situ target RNA detection. 

The seminar highlighted the basis of RNAscope® Technology and labeling protocols, including troubleshooting tips and examples of labeling with both chromogenic and fluorescent dyes.

Research Tapas from the UVM Office of Faculty Affairs -- link to Past Development Events
Vermont Center on Behavior and Health - link to completed lectures